Dee Anna Smith, Chief Executive Officer at Sarah Cannon Research Institute, shared on LinkedIn:
“Every breakthrough in cancer care begins with research.
At Sarah Cannon Research Institute, we’re committed to advancing innovative therapies, expanding access to clinical trials, and accelerating the future of cancer care. As precision medicine and new treatment approaches continue to evolve, collaboration across the oncology ecosystem has never been more important.
Join us at McKesson Accelerate 2026 to engage with leaders and industry experts who are committed to igniting the future of community oncology – because together, cancer doesn’t stand a chance.
If you’ve received your invitation, register today and secure your spot at McKesson Accelerate 2026.”
Other articles featuring Dee Anna Smith on OncoDaily.
